Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Accumulated Expenses: 2010-2025

Historic Accumulated Expenses for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to $90.4 million.

  • Arrowhead Pharmaceuticals' Accumulated Expenses rose 43.48% to $90.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.4 million, marking a year-over-year increase of 43.48%. This contributed to the annual value of $90.4 million for FY2025, which is 43.48% up from last year.
  • As of FY2025, Arrowhead Pharmaceuticals' Accumulated Expenses stood at $90.4 million, which was up 43.48% from $63.0 million recorded in FY2024.
  • Arrowhead Pharmaceuticals' Accumulated Expenses' 5-year high stood at $90.4 million during FY2025, with a 5-year trough of $14.0 million in FY2021.
  • Moreover, its 3-year median value for Accumulated Expenses was $63.0 million (2024), whereas its average is $64.4 million.
  • In the last 5 years, Arrowhead Pharmaceuticals' Accumulated Expenses spiked by 234.66% in 2022 and then dropped by 15.14% in 2023.
  • Yearly analysis of 5 years shows Arrowhead Pharmaceuticals' Accumulated Expenses stood at $14.0 million in 2021, then skyrocketed by 234.66% to $46.9 million in 2022, then fell by 15.14% to $39.8 million in 2023, then spiked by 58.48% to $63.0 million in 2024, then surged by 43.48% to $90.4 million in 2025.